JP2015512406A - ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療 - Google Patents

ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療 Download PDF

Info

Publication number
JP2015512406A
JP2015512406A JP2015503465A JP2015503465A JP2015512406A JP 2015512406 A JP2015512406 A JP 2015512406A JP 2015503465 A JP2015503465 A JP 2015503465A JP 2015503465 A JP2015503465 A JP 2015503465A JP 2015512406 A JP2015512406 A JP 2015512406A
Authority
JP
Japan
Prior art keywords
laquinimod
dmf
amount
day
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015503465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512406A5 (enExample
Inventor
ケイ、ジョエル、フラクスマン
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシューティカル インダストリーズ リミティド, テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2015512406A publication Critical patent/JP2015512406A/ja
Publication of JP2015512406A5 publication Critical patent/JP2015512406A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Exchange Systems With Centralized Control (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015503465A 2012-03-27 2013-03-26 ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療 Withdrawn JP2015512406A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261616337P 2012-03-27 2012-03-27
US61/616,337 2012-03-27
US13/800,047 US20130259856A1 (en) 2012-03-27 2013-03-13 Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
US13/800,047 2013-03-13
PCT/US2013/033885 WO2013148690A1 (en) 2012-03-27 2013-03-26 Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017104051A Division JP2017200927A (ja) 2012-03-27 2017-05-26 ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療

Publications (2)

Publication Number Publication Date
JP2015512406A true JP2015512406A (ja) 2015-04-27
JP2015512406A5 JP2015512406A5 (enExample) 2016-05-19

Family

ID=49235339

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015503465A Withdrawn JP2015512406A (ja) 2012-03-27 2013-03-26 ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療
JP2017104051A Withdrawn JP2017200927A (ja) 2012-03-27 2017-05-26 ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017104051A Withdrawn JP2017200927A (ja) 2012-03-27 2017-05-26 ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療

Country Status (17)

Country Link
US (6) US20130259856A1 (enExample)
EP (1) EP2830623A4 (enExample)
JP (2) JP2015512406A (enExample)
KR (1) KR20150003765A (enExample)
CN (2) CN105853422A (enExample)
AR (1) AR090491A1 (enExample)
AU (2) AU2013239850A1 (enExample)
CA (1) CA2868259A1 (enExample)
EA (1) EA201491773A1 (enExample)
HK (1) HK1205941A1 (enExample)
IL (1) IL234687A0 (enExample)
MX (1) MX2014011616A (enExample)
SG (2) SG11201405755QA (enExample)
TW (1) TW201343164A (enExample)
UY (1) UY34720A (enExample)
WO (1) WO2013148690A1 (enExample)
ZA (1) ZA201407722B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2334378T3 (da) 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
CA2851525A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
AR090073A1 (es) 2012-02-16 2014-10-15 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
US20140348915A9 (en) 2012-08-22 2014-11-27 Xenoport, Inc. Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
JP2015527372A (ja) 2012-08-22 2015-09-17 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
CA2901849A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
EP3110408B1 (en) 2014-02-28 2019-01-16 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
EP3256125B1 (en) 2014-12-11 2022-01-26 Actelion Pharmaceuticals Ltd Dosing regimen for ponesimod, a selective s1p1 receptor agonist
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
GB2540163A (en) * 2015-07-07 2017-01-11 Univ London Queen Mary Combination therapy for treating multiple sclerosis
WO2017120355A1 (en) * 2016-01-06 2017-07-13 Teva Pharmaceutical Industries Ltd. Dihydroquinolines and uses thereof
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
US12483171B2 (en) 2023-12-18 2025-11-25 Abb Schweiz Ag Plug and play solid state controller for high efficiency motors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100130607A1 (en) * 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases
WO2010126605A1 (en) * 2009-04-29 2010-11-04 Biogen Idec Ma Inc. Treatment of neurodegeneration and neuroinflammation
US20100322900A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
WO2011100589A1 (en) * 2010-02-12 2011-08-18 Biogen Idec Ma Inc. Neuroprotection in demyelinating diseases
WO2012101093A2 (en) * 2011-01-25 2012-08-02 Novartis Ag Systems and methods for medical use of motion imaging and capture

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
EP1915387B1 (en) * 2005-07-07 2010-01-20 Aditech Pharma AG Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use
EP2687512A1 (en) 2005-10-19 2014-01-22 Teva Pharmaceutical Industries Ltd. Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof
AU2007258366B2 (en) 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
WO2008097596A2 (en) * 2007-02-08 2008-08-14 Biogen Idec Ma Inc. Nrf2 screening assays and related methods and compositions
US20100260755A1 (en) * 2009-04-09 2010-10-14 Medicinova, Inc. Ibudilast and immunomodulators combination
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100130607A1 (en) * 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases
WO2010126605A1 (en) * 2009-04-29 2010-11-04 Biogen Idec Ma Inc. Treatment of neurodegeneration and neuroinflammation
US20100322900A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
WO2011100589A1 (en) * 2010-02-12 2011-08-18 Biogen Idec Ma Inc. Neuroprotection in demyelinating diseases
WO2012101093A2 (en) * 2011-01-25 2012-08-02 Novartis Ag Systems and methods for medical use of motion imaging and capture

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FARRELL RA AND GIOVANNONI G, J INTERFERON CYTOKINE RES., vol. 30, no. 10, JPN6016045497, pages 715 - 726, ISSN: 0003447657 *
松下 拓也、吉良 潤一: "多発性硬化症−治療の現状と展望− Multiple sclerosis: current therapies and future perspective", 日本臨床 , vol. 第６９巻第１１号, JPN6016045494, November 2011 (2011-11-01), pages 2077 - 2086, ISSN: 0003447656 *
松岡 健: "脱髄疾患の治療の進歩", 神経治療, vol. 26, no. 4, JPN6016045499, 2009, pages 457 - 460, ISSN: 0003447658 *

Also Published As

Publication number Publication date
US20180050031A1 (en) 2018-02-22
US20130259856A1 (en) 2013-10-03
SG11201405755QA (en) 2014-10-30
SG10201607976WA (en) 2016-11-29
EP2830623A4 (en) 2015-09-02
IL234687A0 (en) 2014-11-30
JP2017200927A (ja) 2017-11-09
CA2868259A1 (en) 2013-10-03
ZA201407722B (en) 2016-06-29
EA201491773A1 (ru) 2015-02-27
AU2018200065A1 (en) 2018-02-01
HK1205941A1 (en) 2015-12-31
MX2014011616A (es) 2014-10-17
EP2830623A1 (en) 2015-02-04
AU2013239850A1 (en) 2014-11-06
WO2013148690A1 (en) 2013-10-03
KR20150003765A (ko) 2015-01-09
CN105853422A (zh) 2016-08-17
AR090491A1 (es) 2014-11-19
US20170224675A1 (en) 2017-08-10
US20160000774A1 (en) 2016-01-07
US20170319570A1 (en) 2017-11-09
CN104470520A (zh) 2015-03-25
UY34720A (es) 2013-10-31
US20150119420A1 (en) 2015-04-30
TW201343164A (zh) 2013-11-01

Similar Documents

Publication Publication Date Title
JP2017200927A (ja) ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療
JP2017137298A (ja) ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療
JP2017061482A (ja) ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
JP2017081930A (ja) ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療
JP2017222691A (ja) 多発性硬化症を治療するための高投与量ラキニモドの使用
US20160235735A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fampridine
JP2016510343A (ja) ラキニモドを用いる多発性硬化症の治療
WO2017048457A1 (en) Combination of laquinimod and pridopidine to treat multiple sclerosis
WO2016094516A1 (en) Treatment of multiple sclerosis with combination of laquinimod and a statin
JP2016527270A (ja) ラキニモドおよびフルピルチンの組合せによる多発性硬化症の治療
US20160271094A1 (en) Laquinimod Combination Therapy For Treatment Of Multiple Sclerosis
HK1224600A1 (en) Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
HK1224600A (en) Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
JP2017501230A (ja) ラキニモドおよびテリフルノミドの組合せを用いた多発性硬化症の治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170725

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20171107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171108